#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Adrenogenital syndrome Chondrosarcoma metastatic Vernal keratoconjunctivitis Bile acid synthesis disorder Gastrointestinal disorder Medulloblastoma Heritable pulmonary arterial hypertension Ventricular tachycardia Liposarcoma Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Pulmonary tuberculosis Becker's muscular dystrophy Myocarditis Neuroendocrine cell hyperplasia of infancy Brain abscess More trials…

    Learn about Rare Diseases

    Aicardi-Goutieres syndrome – Treatment Shprintzen-Goldberg syndrome – Treatment Tuberous sclerosis complex – Basic Information Adrenocortical carcinoma – Diagnostics Lymphangioma – Trials in Disease Pleural mesothelioma malignant – Treatment Hereditary optic atrophy Rosai-Dorfman syndrome – Treatment Breast angiosarcoma metastatic – Trials in Disease Hereditary angioedema with C1 esterase inhibitor deficiency – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Histidine Istaroxime Chlorphenamine Xevinapant Clozapine Pantoprazole Patisiran Protrans F1245/05 Salbutamol Sulfate Riboflavin Bp Degarelix Acetate Leriglitazone Tafasitamab Ep0031 Ethambutol Hydrochloride Brexucabtagene Autoleucel Belzutifan Losartan Gsk4004280 More therapies…

    Learn about Your Condition

    Friedreich's ataxia Hand fracture Acne Pathogen resistance Acute cardiac event Ureteric cancer Metabolic surgery Cholangiocarcinoma Pancreatitis chronic Endometrial cancer recurrent Crigler-Najjar syndrome Prostate cancer Deafness bilateral Vertebrobasilar stroke Craniosynostosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Malignant melanoma

  • Study on the Use of Indocyanine Green and Technetium (99mTc) Nanocolloid for Sentinel Node Biopsy in Patients with Melanoma, Oral Cancer, or Penile Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Head and neck cancer
    • Penile cancer
    Investigated Drugs:
    • Human Albumin Solution
    • Indocyanine Green
    The Netherlands

  • Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Neuroendocrine carcinoma of the skin
    • Soft tissue sarcoma
    Investigated Drugs:
    • Bt-001
    • Human Vaccinia Immunoglobulin
    • Pembrolizumab
    Belgium France

  • Study on the Effects of Intradermal IMO-2125 (Tilsotolimod) for Patients with Advanced Melanoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Tilsotolimod Sodium
    The Netherlands

  • Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    • Malignant melanoma
    • Oesophageal squamous cell carcinoma
    Investigated Drugs:
    • Avelumab
    • Dostarlimab
    • Atezolizumab
    France

  • Study on Ceralasertib and Durvalumab for Patients with Advanced Melanoma Resistant to PD-(L)1 Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Ceralasertib
    • Durvalumab
    • Infliximab
    Belgium France Germany Italy Poland Spain

  • Study of Nivolumab for Patients with High-Risk Stage II Melanoma After Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Nivolumab
    Germany
Previous Page
1 … 5 6 7 8 9 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!